Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00292864
Status:
COMPLETED
Last Update Posted:
2012-06-07
First Post:
2006-02-15
Brief Title:
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Sponsor:
Sunesis Pharmaceuticals
Organization:
Sunesis Pharmaceuticals
Study Overview
Official Title:
Phase 1 Open-Label Multicenter Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032 a Novel Cyclin-Dependent Kinase Inhibitor Administered to Patients With Select Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle to define a recommended phase 2 dose and to learn more about the clinical activity of SNS-032
Detailed Description:
Other objectives of this study include measuring pharmacokinetics how long the drug can be measured in the body preliminary evaluation of biomarkers to see how the levels of certain proteins change after administration of SNS-032 assessment of the effects of SNS-032 on QT interval
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None